Advanced Human Imaging (ASX:AHI) - CEO, Vlado Bosanac
CEO, Vlado Bosanac
Source: AHI
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Advanced Human Imaging (AHI) reveals that Tinjoy Biotech’s WinScan app will launch in mid-August 2021
  • In April, the companies signed a marketing agreement for AHI’s BodyScan and FaceScan technology to be integrated into Winscan
  • Tinjoy was hoping to launch the app earlier, in line with the 618-sale held annually in China, but unfortunately did not meet this objective
  • On the market, AHI closed up 8.65 per cent at $1.13 per share

Advanced Human Imaging (AHI) has revealed that Tinjoy Biotech’s WinScan App will launch in mid-August 2021.

In April, the companies signed a marketing agreement for AHI’s BodyScan and FaceScan technology to be integrated into Winscan.

WinScan platform addresses wellness, preventative health and nutrition with the primary focus on identifying individuals at risk of chronic disease.

Tinjoy is a producer of supplements and traditional Chinese medicines based in Guangdong Province.

Tinjoy was hoping to launch the app earlier, in line with the 618-sale held annually in China, but unfortunately did not meet this objective.

Earlier this month, Tinjoy embarked on a pre-registration campaign using its call centre and new marketing platform, The Health Cube. This campaign was successful with 114,391 pre-registrations within a three-day period.

The soft launch of Health Cube was a test designed to find the concurrency and load capacity of the platform through existing Tinjoy customers. However the platform crashed after reaching several hundred thousand engagements.

Tinjoy did not anticipate such high volume concurrent transactions and forced the company to stop taking preregistration. This allowed the development team to make changes to the platform and upgrade the system to allow more transactions.

These upgrades have now been completed ahead of the launch in August.

AHI CEO Vlado Bosanac said to say he was pleased with the confirmation numbers “would be an understatement”.

“With an audience of more than 28,000,000 and a population of over a billion people within China, I am looking forward to seeing what the short-term launch will bring. China is a very health conscious and technology-friendly community,” Mr Bosanac said.

“The key steps from here are to launch the application and commence the consumer growth and acquisition plan Tinjoy are successfully executing on. With a target of one million users by Christmas 2021, we will do all we can to facilitate this with and for Tinjoy.”

Tinjoy Executive Director Russell Bateman said the delay was unfortunate but better for the product.

“The delay was unfortunate, but I believe we have a better product to offer our millions of consumers and preregistered parties,” he said.

“My first step will be to action the current preregistrations to downloads, and the marketing team will execute on next steps to continue the interest and growth we saw from the initial campaign to achieve the one million-user target we have undertaken with AHI.”

On the market, AHI closed up 8.65 per cent at $1.13 per share.

AHI by the numbers
More From The Market Online

What it takes to get a new drug to market in Australia

In this latest version of Thematica from TMO, we're taking a break from mines and battery…

4DMedical partners with West Los Angeles VA Medical Center for Veteran lung imaging study

Respiratory imaging technology company, 4DMedical (ASX:4DX) has entered into a research agreement with the West Los…

Recce Pharma picks up Chinese patent for anti-infective drugs

Recce Pharmaceuticals (ASX:RCE) has confirmed its receipt of a patent in China to protect its class…

BlinkLab partnership with US smart-tech Turning Pointe raises hopes for autism kids

BlinkLab partners with US-based Turning Pointe Autism Foundation for clinical study ahead of its FDA registration…